Search
Bronopol
go.drugbank.com/drugs/DB13960ApprovedCompared to other aliphatic halogen-nitro compounds, bronopol is more stable to hydrolysis in aqueous media under normal conditions [A32792].
Chlormerodrin
go.drugbank.com/drugs/DB00534ApprovedWithdrawnIt is no longer used and has been replaced with new classes of diuretic drugs.
Anistreplase
go.drugbank.com/drugs/DB00029ApprovedWithdrawnA p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins.
Cinitapride
go.drugbank.com/drugs/DB08810InvestigationalCinitapride is a gastroprokinetic agent and antiulcer benzamide with agonist activity at 5-HT1 and 5-HT4 receptors and antagonist activity at 5-HT2 receptors. It is marketed in Spain and Mexico.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeRelaxin receptor 2
go.drugbank.com/bio_entities/BE0017729TargetHumansReceptor for relaxin. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP. May also be a receptor for Leydig insulin-like peptide (INSL3)
Synonyms: Leucine-rich repeat-containing G protein-coupled receptor 8Pleconaril
go.drugbank.com/drugs/DB05105Investigationalhave had exposure to _picornavirus_. … Food and Drug Administration (FDA) due to the fact that it has been found to induce CYP3A enzyme activity, therefore increasing the risk for serious drug interactions.
Cryptenamine
go.drugbank.com/drugs/DB00785ApprovedCryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known.
WX-UK1
go.drugbank.com/drugs/DB05476InvestigationalWX-UK1 is a 3-amidinophenylalanine-based non-cytotoxic small molecule that belongs to a new class of drugs. … In animal models, WX-UK1 blocks tumor cell invasion, metastasis and primary tumor growth by inhibiting serine proteases and the urokinase Plasminogen Activator (uPA) system, which have been shown to play
Besifloxacin
go.drugbank.com/drugs/DB06771ApprovedBesifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.
Cephalexin
go.drugbank.com/drugs/DB00567ApprovedInvestigationalVet approved[A179071] Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.[A179083,L6547] Cephalexin was approved by the FDA on 4 January 1971.